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Abstract
Background: Chronic pancreatitis (CP) is a progressive inflammatory disorder currently 
diagnosed by morphologic features. In contrast, an accurate diagnosis of Early CP is not possible 
using imaging criteria alone. If this were possible and early treatment instituted, the later, 
irreversible features and complications of CP could possibly be prevented.
Method: An international working group supported by four major pancreas societies (IAP, APA, 
JPS, and EPC) and a PancreasFest working group sought to develop a consensus definition and 
diagnostic criteria for Early CP. Ten statements (S1–10) concerning Early CP were used to gauge 
consensus on the Early CP concept using anonymous voting with a 9 point Likert scale. Consensus 
required an alpha ≥0.80.
Results: No consensus statement could be developed for a definition of Early-CP or diagnostic 
criteria. There was consensus on 5 statements: (S2) The word “Early” in early chronic pancreatitis 
is used to describe disease state, not disease duration. (S4) Early CP defines a stage of CP with 
preserved pancreatic function and potentially reversible features. (S8) Genetic variants are 
important risk factors for Early CP and can add specificity to the likely etiology, but they are 
neither necessary nor sufficient to make a diagnosis. (S9) Environmental risk factors can provide 
evidence to support the diagnosis of Early CP, but are neither necessary nor sufficient to make a 
diagnosis. (S10) The differential diagnosis for Early CP includes other disorders with 
morphological and functional features that overlap with CP.
Conclusions: Morphology based diagnosis of Early CP is not possible without additional 
information. New approaches to the accurate diagnosis of Early CP will require a mechanistic 
definition that considers risk factors, biomarkers, clinical context and new models of disease. Such 
a definition will require prospective validation.
Introduction.
Chronic pancreatitis (CP) is one of the most difficult medical disorders to diagnose early and 
treat effectively. Advanced or End-stage CP is a well-described syndrome consisting of 
structural features of fibrosis, duct distortion, calcifications and/or atrophy, along with 
variable dysfunctional features of severe chronic pain, maldigestion and diabetes mellitus, 
and a long-term risk of pancreatic cancer. Patients with End-Stage CP typically struggle with 
pain relief, stigmatization, unemployment, and depression and often have among the worst 
quality of life measures for any chronic disease (1–3).
Tremendous effort and resources continue to be directed towards patients with end-stage 
disease. To avoid late stages complications and to improve clinical outcomes, diagnosis and 
treatment are essential at an early stage before CP becomes established and irreversible (4). 
Thus, it is important that increased efforts are directed towards early detection and targeted 
therapy in the hope of mitigating disease progression and improving the quality of life in a 
cost-effective, precision medicine approach (5).
The challenge in clinical care of patients with syndromes such as CP is that a “definitive 
diagnosis” is often only possible too late in the disease course to initiate treatments that 
might limit progression and/or minimize complications (4). Furthermore, between the onset 
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of various nonspecific signs and symptoms and the definitive diagnosis of CP by 
morphologic criteria, the patient often suffers from years of pain and distress while 
undergoing frequent diagnostic testing, such as in hereditary pancreatitis with an average 
delay of 9–10 years between symptom onset and a diagnosis (6, 7). In patients with atypical 
presentation and/or limited fibrosis (e.g. Cambridge score of <3 and/or not meeting 
Rosemont Criteria on EUS (8)) the diagnosis may be further delayed or missed altogether. 
Other consequences of delaying a definitive diagnosis include withholding effective 
treatments and/or giving inappropriate treatments (9).
A better understanding of the development, progression and treatment of CP is required. 
With that in mind, international experts have sought consensus on definitions, features and 
biomarkers related to the stages of CP. First, a mechanistic definition of CP was developed 
to better structure the features, interactions and stages of CP, and this definition was adopted 
by the major international pancreas organizations (10). A mechanism-based approach to 
assessment and management of pancreatic pain was published in 2017, taking into 
consideration the multidimensional nature of clinical presentation and variable response to 
specific therapies (11). Guidelines for the Diagnostic Cross Sectional Imaging and Severity 
Scoring of Chronic Pancreatitis have also been developed (submitted). But one of the most 
challenging areas for developing consensus is in Early CP because a definitive diagnosis of 
CP is impossible using the widely accepted imaging criteria (12). However, it may be 
possible to make a diagnosis of Early CP, in some cases, when CP is framed using the 
recently endorsed mechanistic definition and progression model (10). The aim was to 
determine whether consensus could be achieved for the definition and diagnostic criteria for 
Early CP and to highlight areas for further basic, translational and clinical research.
Historical definitions of Chronic Pancreatitis
Historically, the diagnosis of the CP syndrome was based on the triad of steatorrhea, 
pancreatic calcifications on abdominal X-ray and diabetes mellitus – evidence of end-stage 
disease. Early attempts to systematically define CP by morphologic, functional and clinical 
criteria occurred between 1963 and 1988 with three “Marseille” conferences (13–15). These 
conferences were fundamental in defining the characteristics of CP, but were relatively 
limited at the that time because of limited understanding of the complex risk factors for CP, 
particularly genetic, lack of sensitive imaging techniques and inadequate biomarkers of 
disease activity and progression. As a result the focus was necessarily on advanced CP with 
gross morphological features (16).
Significant improvements in abdominal imaging in the 1980s with computed tomography 
(CT), magnetic resonance imaging (MRI) and endoscopic retrograde 
cholangiopancreatography (ERCP) allowed more accurate assessments of morphologic 
changes, including the earlier stages of CP. An International Workshop held in Cambridge, 
England in March 1983 advanced the field with a working definition of CP based on 
morphology of the pancreas by ERCP imaging features, and an image-based severity scale 
(Cambridge Score) (12). The committee also recognized the limitations of imaging in 
making an early diagnosis. The conference report noted that the delegates “discussed the 
need for a grouping intermediate between acute and chronic pancreatitis, perhaps only as a 
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‘holding grade’ before final classification. This concept was eventually rejected, it being 
assumed that most clinicians would naturally use the term ‘probable chronic pancreatitis’ 
where necessary.” (12)
‘Early’ Chronic Pancreatitis.
The term “early-stage ACP” was used by Ammann, Heitz and Klöppel (17) to define a 
clinical stage linking alcoholic AP (AAP) and alcoholic CP (ACP). They argued that the 
diagnosis ‘early-stage ACP’ must be confirmed by criteria independent from histology, such 
as “long-term follow-up that eventually revealed the typical clinical features of CP” (17). 
Since Early-stage ACP could not be diagnosed with available clinical tests, the delegates to 
the 1996 Zürich Workshop used the term “Probable ACP” to describe the early phases of CP, 
typically lasting at least 5 years before “Definite ACP” could be diagnosed using 
morphologic features of End-stage CP. Thus, they defined a clinically important early stage 
that, at the time, could only be diagnosed in retrospect.
The majority of subsequent classification systems and consensus guidelines follow the 
Cambridge and Zürich Workshop recommendations of using morphologic criteria and 
applying the term “Probable CP” for cases with a high likelihood of CP but which do not 
meet imaging criteria of definite CP (18–21). For example, The M-ANNHEIM classification 
system follows the Zürich definitions, except for altering the criteria for “probable ACP” to 
“Borderline CP” for patients with “typical symptoms of chronic pancreatitis (i.e., recurrent 
episodes of acute pancreatitis) or with a first episode of acute pancreatitis who present 
without any morphological damage visible by means of pancreatic imaging techniques or 
detectable functional insufficiency suggestive of chronic pancreatitis” (22). The American 
Pancreatic Association (APA) Practice Guidelines in Chronic Pancreatitis (9) provided no 
definition for CP, but suggested classification of patients as “Definitive”, “Probable”, and 
“Insufficient” based on imaging studies or histology. The authors also recommended that 
patients in early stages should not be classified as having CP until definitive diagnostic 
features are evident (9). Most recently the United European Gastroenterology published 
guidelines for the diagnosis of CP (23), following the German S3 guidelines (18, 19) stating 
that the diagnosis of CP should be based on imaging modalities, but emphasized that 
imaging should be performed in symptomatic patients presenting with indicators suggestive 
of pancreatic disease. This reflects the Marseille approach where the diagnosis of CP is 
based on morphologic, functional and clinical criteria, but still with a focus on advanced 
disease.
In summary, these approaches recognized the existence of an early stage in progression of 
CP, but also recognized that the signs and symptoms of early disease are nonspecific, that 
progression is uncertain using the imaging approach to CP (8, 12) and that the diagnostic 
criteria required for a definitive diagnosis of CP using imaging techniques alone are not met. 
However, “Probable CP” (here used interchangeable with “Borderline CP”) is not a 
diagnosis, but rather a “placeholder” state, for those in whom CP high on the differential 
diagnosis list and is considered highly likely. The term “Possible CP” means that that CP 
ranks lower in the differential diagnosis list than other more likely diseases.
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The Japan Pancreas Society (JPS) was the first major body to provide criteria for the 
diagnosis of Early CP (4). The 2009 revision of the diagnostic criteria for CP used the terms, 
“Definite CP”, “Probable CP”, and “Early CP” to classify pancreatic disease patients (4). 
The JPS “Definite CP” and “Probable CP” diagnosis are based on imaging criteria for 
“Advanced CP Findings” and “Probable CP Findings”, respectively (Figure 1). Subjects 
with imaging findings of Probable CP, but who also have two or more of the first three JPS 
functional/clinical findings (Table 1) are diagnosed with “Definite CP”. The JPS definition 
of “Early-CP” requires that cases do not qualify for a “definite” or “probable” diagnosis, that 
they satisfy two or more of the 4 functional/clinical criteria (including persistent drinking 
history of >80 g/day), and demonstrate appropriate imaging findings (4). These imaging 
criteria are based on EUS and/or ERCP examination. The definition of “Possible CP” 
requires that the patient meet the functional/clinical criteria, but do not meet imaging criteria 
(4, 24).
While the JPS approach provides a potentially useful definition of Early CP, it has not been 
accepted internationally. This might be because of two limitations: that the imaging criteria 
have low specificity for Early CP and that continued alcohol use is a requirement. To make 
progress towards a definition and diagnostic criteria for Early CP, these limitations need to 
be overcome and a new paradigm introduced.
Mechanistic Definition of CP.
A new mechanistic definition of CP was proposed to define the mechanism of disease and 
the typical characteristics of established disease (10). In the mechanistic definition, “Chronic 
pancreatitis is a pathologic fibro-inflammatory syndrome of the pancreas in individuals with 
genetic, environmental and/or other risk factors who develop persistent pathologic responses 
to parenchymal injury or stress.” and “Common features of established and advanced CP 
include pancreatic atrophy, fibrosis, pain syndromes, duct distortion and strictures, 
calcifications, pancreatic exocrine dysfunction, pancreatic endocrine dysfunction and 
dysplasia.” Thus, the Mechanistic Definition does not require imaging features to define the 
disease.
Reliance on imaging as an essential requirement for the diagnosis of CP hinders the 
possibility of making early and definitive diagnoses of Early-CP. Initially, the diagnosis was 
hampered by limited sensitivity – but with improvements in imaging technology, the 
specificity of minor morphologic changes becomes the major challenge (25). Furthermore, 
current imaging techniques do not allow for the assessment or measure of most risk factors, 
degree of organ function, disease mechanism or disease activity.
The diagnosis of Early-CP requires a change in the way the CP disease is understood and 
managed. The mechanistic definition of CP (10) introduces a different framework for 
understanding and managing CP within the emerging concepts of precision medicine (5). 
Chronic pancreatitis is viewed as a complex disorder arising in high-risk subjects and 
progressing to end stage disease over time. More specifically, acquired diseases such as CP 
are more likely to develop in patients with one or more underlying molecular disorders, such 
as pathogenic PRSS1, SPINK1, CFTR, CTRC, CEL and CLDN2 genetic variants within a 
stress-provoking environmental context (26–30) and in a clinical context such as RAP. The 
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new definition is built on a progressive model of CP beginning with an asymptomatic “At 
Risk” stage and progressing over time, in some individuals, to “End-Stage CP”. This 
approach is inclusive of any susceptibility or modifying factors causing dysfunction of the 
normal process of Injury → Inflammation → Resolution → Regeneration originating in 
cells of the exocrine pancreas that ultimately lead to the characteristic pathological features 
of CP. The mechanistic definition also excludes disorders that cause pathology in the 
pancreas by different mechanisms, such as extrinsic duct obstruction, fibrosis from the 
desmoplastic reactions in pancreatic cancer or the pancreatopathy of long-standing diabetes 
mellitus and other disorders (25). Since the mechanistic definition of CP defines the process 
leading to the end-stage features of true CP, the earlier detection of this process has the 
potential to provide new diagnostic criteria for Early CP, including consideration of patients 
who are symptomatic but do not meet traditional imaging criteria for CP. Implementation of 
this mechanistic definition in clinical practice could prove beneficial in better defining and 
managing patients who are symptomatic of pancreatic disease, but in whom imaging results 
are non-specific or inconclusive for CP.
Goals and Objectives of an International Consensus Working Group on Early CP
Chronic pancreatitis is recognized as a heterogeneous syndrome that typically progresses 
from acute, recurrent and/or continuous inflammation of the pancreas to destructive and 
irreversible end-stage disease (10). Because of the complexity of CP and the differences 
between countries and populations, it is important that an advance in the understanding of 
this disease draws on international experience and expertise. This challenge is particularly 
relevant to the definition and diagnosis of Early CP where it is necessary to consider new 
ways to frame the disease, including the precision medicine paradigm that allows multiple 
interacting factors to be considered in parallel and sequence (5).
An international effort, including sixteen working groups was organized and commissioned 
to develop international consensus guidelines for the understanding and management of 
chronic pancreatitis in collaboration with the International Association of Pancreatology 
(IAP), American Pancreatic Association (APA), JPS and the European Pancreatic Club 
(EPC). The sub-group on Early CP (Chair; DCW) encompassing experts from the four 
major pancreas societies (IAP, APA, JPS, and EPC) and a PancreasFest working group.
Goals included:
1. To identify and invite a working group of international experts on the methods 
and criteria of the diagnosis of chronic pancreatitis.
2. To review the existing literature and emerging technologies related to Early CP
3. To hold an international consensus conference on Early CP that would be 
cosponsored by the IAP.
4. To develop an international consensus definition of Early CP.
5. To discuss and potentially develop consensus guidelines on the diagnosis of 
Early CP.
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The first three goals were achieved. The last two goals were not achieved, but significant 
progress was made in defining the issues surrounding Early CP, and outlining the needs for 
future research.
Methods
The first approach to developing an international consensus on the definition of CP was a 
“consensus of consensus guidelines” promoted by the organizers of the combined EPC / IAP 
Meeting in Southampton, UK in June 2014. The outcome of this meeting was a draft 
Mechanistic Definition of CP (10) as described earlier. This was presented and accepted by 
voting members of the respective organizations during special sessions of the European 
Pancreas Club in Liverpool, UK (July 9, 2016), PancreasFest 2016 in Pittsburgh, PA, USA 
(July 27, 2016) and the combined international Association of Pancreatology (IAP), Japan 
Pancreas Society (JPS) and the Asian-Oceanic Pancreatic Association (AOPA) joint meeting 
(IAP/JPS/AOPA) in Sendai, Japan on August 6, 2016.
During the 2016 EPC meeting, John P Neoptolemos, David C Whitcomb and Tooru 
Shimosegawa agreed on a joint venture to produce international consensus definitions and 
guidelines on CP with endorsement from the four International societies. The Mechanistic 
Definition of CP was used as a starting point, including a conceptual disease model that 
outlined a sequence of five disease stages representing the progression of CP from pre-
disease state to end-stage features (10). The stages were defined as Stage A, “At Risk”; 
Stage B, “AP-RAP”; Stage C, “Early CP”; Stage D, “Established CP”; and Stage E, 
advanced or “End Stage CP”. This progressive model was designed to organize the 
numerous biomarkers of disease state and disease activity within time frames, to aid in 
defining diagnostic criteria, disease subtypes, disease trajectory toward defined endpoints 
and effectiveness of treatments. Stage C, “Early CP” was included as a ‘place-holder’ while 
the minimum essential criteria for defining Stage C and Stage D were left for future 
discussions.
On August 6, 2016, a special session of the combined meeting of the IAP/JPS/AOPA was 
held in Sendai, Japan entitled “What is early chronic pancreatitis and why is diagnosis 
important?” Fourteen invited experts presented their perspectives on the question of “Early 
CP” based on a review of data from the relevant literature combined with their clinical 
experiences. The method of systematic literature review of major consensus reports, invited 
expert reviews, systematic reviews, and landmark papers that were published between 1965 
and 2016 on recurrent acute pancreatitis (RAP) and CP was previously described (10). The 
international experts provided data and a range of opinions on multiple issues, and no overall 
consensus was reached. Subsequently at the joint IAP/Latin American Pancreas Club 
meeting in Buenos Aires in September 2017, it was agreed to consider 10 statements for 
which the level of consensus was determined.
Grading evidence
Prior to starting, the international experts were asked to vote on their preferred system for 
rating the quality of evidence, which would be used in the international guidelines 
recommendations. The decision was to use the Grading of Recommendations Assessment, 
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Development, and Evaluation (GRADE) approach, as adapted for “UpToDate” (http://
www.uptodate.com/home/grading-tutorial). The quality of evidence supporting the ten 
statements was graded as (i) “high” if there was very low probability of further research 
substantially changing the conclusions, (ii) “moderate” if further research might completely 
change the conclusions, and (iii) “low” if further research was likely to completely change 
the conclusions.
Defining consensus
The ten statements were then voted on by the working group of international experts that 
participated in the meetings and discussions for strength of agreement, using a 9-point Likert 
scale. The results were used to calculate Cronbach’s alpha reliability coefficient (http://
hdl.handle.net/1805/344). The results were classified under “agreement” as either; strong 
(≥80% of votes were 7 or above), conditional (≥65% of votes were 7 or above), and weak 
(<65% of votes were 7 or above). In addition, explanatory comments were compiled to 
frame the issues surrounding the statement, supported by key references. The final results 
were tabulated. Based on these results a final draft of the document was generated and 
circulated to all the authors for final editing and approval.
Results
The ten statements (S) relating to ten questions (Q) for the definition and diagnostic criteria 
of Early-CP are provided with the consensus in respect of the quality of Evidence, strength 
of Recommendation and degree of Agreement, in addition to the Cronbach’s alpha 
reliability coefficient (‘alpha’).
Q1. What is Early Chronic Pancreatitis?
S1. The term Early Chronic Pancreatitis describes the initial stage of definite 
chronic pancreatitis.
(Quality assessment: low; Recommendation: conditional; Agreement: conditional).
Alpha Agreement: 0.77
Explanation: Chronic pancreatitis is an acquired disease that occurs due to a variety of 
causes and has a progressive course. From a normal pancreas to a state of established 
chronic pancreatitis, the disease must progress through an intermediate state characterized 
by subtle features of CP regardless of clinical manifestations or pace of such progression.
Making a definite diagnosis of CP is important for several reasons. First, establishing a 
diagnosis provides answers to the patient as to the cause of signs and symptoms of disease 
that they may be experiencing. Second, it excludes or minimizes further diagnostic testing 
for other disorders within the differential diagnoses. Third, there is prognostic significance 
linked to the natural history of the disease. Fourth, it has management implications, both for 
symptomatic relief and limiting disease progression. Fifth, it triggers strong 
recommendations to avoid further alcohol or tobacco consumption.
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A few of the working group members were concerned about the use of the term “definite” 
(suggesting that a critical number of yet-to-be-defined criteria need to make a diagnosis of 
CP had been met). Specifically, in the setting of subtle and/or non-specific imaging features 
a premature or inaccurate diagnosis of “definite” CP may result in inappropriate radical 
treatments such as total pancreatectomy with islet autotransplantation (TPIAT) (31).
It was generally agreed, but not unanimously, that if the diagnosis of Early-CP were based 
on imaging criteria alone, a “definite” diagnosis could not be made (See Statement 5). To 
some experts the term “Early CP” itself was incompatible with the term “definite” and 
should be considered equivalent to “Possible CP” or “Borderline CP”. In contrast, others 
argued that, in clinical context the term “Definite CP” is relative. It does not mean 100% 
accuracy, but rather an acceptable accuracy for the purposes of clinical classification. The 
idea of “acceptable” balances the concepts of risk versus benefit when making a “definite” 
diagnosis of CP (see Statement 6). It was further recognized that a subset of patients 
classified by imaging criteria as “Possible CP” who also have high-risk etiologic factors (e.g. 
highly pathogenic genetic mutations or heavy alcohol consumption), a clinical setting of AP 
or RAP might be classified as Early-CP. In contrast, other patients with similar imaging 
findings but without high-risk etiology factors or RAP should not be given a diagnosis of 
Early-CP, especially if other diagnoses have not been excluded such as IPMN or acinar cell 
cystadenoma (25).
The idea of “accurately” diagnosing CP prior to advanced imaging findings was considered 
“possible” by most of the working group under some conditions, such as in an individual 
with genetic risk, RAP and “some” features of CP on abdominal imaging (see Statement 6). 
However, since there is low quality of evidence to support this statement, only moderate 
consensus was reached (alpha 0.77).
There was agreement that future studies are required to confirm that CP can be accurately 
diagnosed by new approaches before the development of imaging features of Established CP 
and End Stage CP are detected. to meeting historically established imaging criteria. Until 
such time there may be some uncertainty associated with the diagnosis of Early CP because 
of various conditions that may cause similar histological or morphological changes in the 
pancreas, such as aging and diabetes (Table 2). The benefit of integrating the probabilistic 
advantages of genetic testing with documented environmental factors within appropriate 
clinical settings to define and accurately diagnose Early CP needs to be tested in prospective 
studies.
Q2. What does the word “Early” mean in the definition of Early Chronic Pancreatitis.
S2. The word “Early” in early chronic pancreatitis is used to describe disease state, 
not disease duration.
(Quality assessment: moderate; Recommendation: strong; Agreement: strong).
Alpha Agreement: 1.00
Explanation: Early CP is distinguished from Established CP and End-Stage CP by the 
absence of features of advanced CP (10). The rate of progression from Early CP to 
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Established CP and End-Stage CP varies greatly and the basis of the variation is unclear. It 
follows that the duration of Early CP cannot be defined.
Q3. What does the word “chronic” mean in the definition of Early Chronic Pancreatitis?
S3. The word “Chronic” in early chronic pancreatitis is used to describe disease 
character and duration.
(Quality assessment: moderate; Recommendation: strong; Agreement: conditional).
Alpha Agreement: 0.69
Explanation: The working group members disagreed on what the word “chronic” meant in 
the context of Early-CP. The work “character”, linked to the Mechanistic Definition, refers 
to the molecular characteristic of chronic injury or stress and/or the pathologic response to 
the Injury → Inflammation → Resolution → Regeneration sequence. Some working group 
members still believed that “character” refers more to the morphologic characteristics of 
more advanced stages as used in the Cambridge Score or the Established CP/End-Stage CP 
phases of the mechanistic definition. From this perspective they considered that this term 
was an ‘oxymoron’ in Early CP, as chronic morphologic features cannot occur at an early 
stage. Thus, the term “chronic” defined by features of the late stages of CP and applying it to 
Early CP may be misplaced.
To qualify for the term “chronic” pancreatitis on the basis of the Mechanistic Definition, 
there needs to be evidence of ‘a persistent pathologic response’ (10). This amounts to a 
dysregulation and pathologic persistence of the expected inflammation, recovery and 
regeneration sequence, and indicates an active and progressive pathogenic response linked to 
acinar cells and/or duct cells, depending on the underlying mechanism of injury or stress. 
Furthermore, these changes do not occur in the normal response to AP or RAP. There are, 
however, no widely accepted biomarkers that distinguish the response to AP and RAP from 
CP. Thus, the term “character” depends on the definition of CP, and the corresponding 
disease concepts and models.
The working group members offered different opinions regarding the term “duration”. The 
U.S. National Center for Health Statistics describes a chronic disease as one that last for 
three months or more, but the literature uses the term “chronic disease” variably and it 
depends on the data used for the research and the discipline of the lead authors (32). There 
were some members of the working group that agreed that a period of persistent pathologic 
response for greater than 6 months after AP or RAP was a reasonable and pragmatic 
threshold for the diagnosis of Early CP while others advocated for at least 12 months. Some 
also argued that within that time frame (6 or 12 months) there should be detection of “at 
least some” morphological features diagnostic of Established CP but not enough for 
definitive diagnosis of CP.
Q4. How does Early Chronic Pancreatitis affect pancreatic function?
S4. Early chronic pancreatitis defines a stage of CP with preserved pancreatic 
function and potentially reversible features.
Whitcomb et al. Page 10
Pancreatology. Author manuscript; available in PMC 2019 November 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(Quality assessment: low; Recommendation: strong; Agreement: strong).
Alpha Agreement: 0.83
Explanation: There are two components to this statement. Preserved pancreatic function 
means that viable parenchymal tissue remains that can function in terms of generating 
pancreatic digestive enzymes from acinar cells and secreting a bicarbonate-rich fluid from 
the duct cells. Secondly, the Early CP stage may be early enough that some of the lost 
functional features may return with appropriate treatment. The first concept recognizes a 
gradient from normal function to complete loss of function or organ failure, with the Early 
CP stage being closer to normal. The second concept is more difficult, because it suggests 
that there is a point in CP severity where the damage is irreversible and there is no chance of 
recovery.
There is little clinical evidence for the reversibility of impaired pancreatic function (or 
fibrosis) in CP, although this remains a research aim in developing therapies targeting the 
drivers of CP. However, there are several observations which suggest the potential for 
reversibility in Early-CP
First, in humans, viral hepatitis may lead to liver fibrosis (cirrhosis) and liver failure. 
However, new therapies for hepatitis B and hepatitis C that eliminate the virus can result in 
reversal of fibrosis and improvement in liver function (33–36). Histological regression of 
cirrhosis occurs in only a subset of patients and regression is more likely if the fibrosis 
occurred more recently, if there is effective and long-lasting viral suppression, if there is 
internal capacity to regenerate and if there is no vascular thrombosis (33). Regression of 
fibrosis also occurs in patients with common bile duct stenosis after biliary drainage (37). In 
the liver, elimination of the source of injury is the primary condition needed for the 
regression of cirrhosis, and patients with regression have better clinical outcomes than those 
who do not (36–38). These data indicate that reversal of fibrosis in humans is possible, and 
that in some cases of liver disease, function is at least partially restored.
Second, in animal models of CP, recurrent injury to the pancreas with cerulein-induced 
hyperstimulation to causing AP and RAP leads to pancreatic fibrosis (39–42). Discontinuing 
cerulein injections leads to resolution of the fibrosis and regeneration of normal pancreatic 
tissue, depending on the severity of damage over time (39). This observation indicates that 
elimination of the inflammatory driver at earlier stages can lead to regression in 
experimental models pancreatic fibrosis.
Third, there are conditions in humans in which exocrine pancreatic insufficiency resolves. 
Patients with autoimmune pancreatitis may have exocrine and/or endocrine pancreatic 
insufficiency, and these insufficiencies improve after steroid therapy (43), showing that the 
functional loss is reversible. Finally, pancreatic insufficiency is seen after AP, and generally 
reverses during recovery (44, 45). EPI may persist after AP in up to a third of patients (46–
50), but in some cases the EPI resolves with time (51).
This statement therefore defines the concept of reversibility, within limits, of lost exocrine 
function in Early CP. Future studies are needed to determine whether there are specific 
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subtypes of CP that have a component of reversible pancreatic functions with targeted 
therapies. The line between reversible and irreversible function loss has yet to be 
determined, but will vary depending on the number of factors including the particular 
function, the severity of functional impairment and the efficacy of the treatment.
Q5. Can Early Chronic Pancreatitis be diagnosed by abdominal imaging techniques alone?
S5. Early Chronic Pancreatitis cannot be diagnosed based on currently available 
imaging techniques alone.
(Quality assessment: moderate; Recommendation: strong; Agreement: conditional).
Alpha Agreement: 0.77
Explanation: Continuing improvement in abdominal imaging techniques have allowed 
more subtle changes in pancreatic structure to be detected. And while these imaging features 
are taken as surrogate for histological changes such as fibrosis, these findings are 
nonspecific (25). Many imaging features of Early CP overlap with other conditions 
associated with mild fibrosis, atrophy or altered morphology including old age, long-
standing diabetes mellitus, alcohol abuse without AP, and smoking without AP (52–54) 
(Table 2). EUS is considered the most sensitive modality for detecting Early CP (19, 23), 
although the number and type of diagnostic criteria continue to be debated (55). EUS does 
offer quantitative measures that are useful for staging severity of structural changes, 
calcifications, and fibrosis, especially when coupled with elastography (56–60). 
Furthermore, some patients with definite CP on histology have “normal” EUS using 
Rosemont criteria for CP (8). However, in general, as the threshold number of EUS criteria 
increases, the specificity for a diagnosis of CP increases but the sensitivity decreases (61). 
Since current imaging technology cannot measure and differentiate between the various 
pancreatitis-related or other etiologies of inflammation or fibrosis, it cannot be 
recommended for this purpose.
In contrast, some of the working group members argue that the Early-CP can be diagnosed 
by EUS criteria in the hands of expert physicians. Others suggested that although Early-CP 
cannot be diagnosed by abdominal imaging techniques now, it may be possible in the future 
as technology advances, especially with inclusion of functional measures. Future prospective 
studies are required to determine the accuracy of diagnosing Early CP in populations with 
patients with other disorders with similar or overlapping imaging features.
Q6. Can Early Chronic Pancreatitis be diagnosed by a combination of factors?
S6. Theoretically Early CP can be diagnosed based on a combination of (a) the 
presence of high risk factors for CP, (b) low risk for other disorders with features 
that overlap CP, (c) appropriate clinical context and (d) supportive biomarkers
(Quality assessment: low; Recommendation: strong; Agreement: weak).
Alpha Agreement: 0.62
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Explanation: The working group could not reach consensus on the diagnostic criteria for 
Early CP, although there was general agreement that it should be possible to make a fairly 
accurate diagnosis with the right combination of yet-to-be-determined criteria. There was 
agreement that some clinical features favored the diagnosis of CP, while other features either 
favored alternative diagnoses, or were nonspecific (Table 1). The working group also agreed 
that in addition to a combination of risk factors associated with CP, the clinical context and 
supportive biomarkers were all necessary to establish a “probable” diagnosis of Early CP. 
However, there was only a moderate level of consensus for the statement that a “definitive 
diagnosis” of Early CP could be made (see Statement 1 discussion).
Currently, a diagnosis of CP using imaging criteria is possible when there are advanced 
morphologic changes, but this precludes a diagnosis of early CP. The problem with using 
morphology as the sole diagnostic criteria for CP is that imaging findings do not correlate 
with pain, with disease activity or important outcomes (62, 63). This is especially important 
because clinical management of pancreatitis patients typically focuses on inflammation, pain 
and dysfunction rather than on fibrosis. Thus, the tradeoff of using advanced features of the 
Cambridge Score for a “definitive” diagnosis of CP is very low sensitivity for earlier phases 
of CP in exchange for higher specificity late in the disease. An alternative approach is 
needed that will improve both sensitivity and specificity.
Given that morphological features cannot be relied on for the accurate diagnosis of Early CP, 
other factors will be necessary. The hope is that the mechanistic definition of CP (10), which 
takes into account risk factors, biomarkers of inflammation, pain and functional status within 
the clinical context, will provide a framework for the development of diagnostic criteria that 
will allow the accurate diagnosis of Early CP.
Biomarkers objectively measure and biological and pathogenic processes (64, 65). 
Biochemical analytes, pain scales, imaging features, function tests and histology can each be 
used as biomarkers of different aspects of pancreatic health or disease to determine disease 
stage, state, trajectory or response to treatment. Since RAP and CP are complex disorders 
affecting multiple systems with variable responses, one biomarker, such as a pancreas image, 
cannot serve as a surrogate for all other biomarkers. Biomarkers without a defined context 
are also problematic since they are typically derived from naturally occurring features that 
become abnormal through statistically significant (+/− standard deviation) changes from 
normal in location, amount or timing of the feature. Thus there are inherent challenges with 
sensitivity and specificity; especially since specificity calculations are dependent on the 
population within which the biomarker is tested (66). Indeed, the issue of specificity raised 
the most concern among the working group members that opposed supporting a diagnosis of 
Early CP using imaging criteria alone.
The mechanistic definition of CP includes risk factors as a central part of the definition. 
Unlike biomarkers, risk factors are attributes, characteristics, or exposures that increase the 
likelihood of developing an injury or disease. A number of risk factors for CP, and the 
relative risk or risk ratio (RR) for many of these factors have been calculated (3, 67–69). 
Selecting patients with high risk effectively increase the prevalence of disease within the 
population being evaluated (70) and therefore improves the positive predictive value of the 
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biomarker-based test. Excluding patients with other disorders further increased the accuracy 
by removing potential false positive individuals. The probability that a biomarker of Early 
CP can provide and accurate diagnosis is influenced by the clinical context, and in particular 
the presence of risk factors. For example, a history of heavy alcohol use or RAP will 
increase the accuracy of a diagnostic biomarker of Early CP
Q7. Is acute pancreatitis a mandatory risk factor for Early Chronic Pancreatitis?
S7. A history of acute pancreatitis, and especially recurrent acute pancreatitis, are 
significant risk factors for early chronic pancreatitis, but are not mandatory to make 
a diagnosis.
(Quality assessment: low; Recommendation: conditional; Agreement: weak).
Alpha Agreement: 0.62
Explanation: Animal models of CP, clinical case series and multiple epidemiological 
studies have established that AP often, but not always, precedes CP (47, 49, 50, 71–75). It is 
generally accepted that AP is associated with the sequence of Injury → Inflammation → 
Resolution → Regeneration (10). The likelihood of CP developing is higher in patients with 
previous RAP than previous AP (76). Since AP and RAP are both major risk factors for CP, 
it follows that AP and RAP are also risk factors for Early CP. The members of the working 
group agreed that evidence for a diagnosis of Early CP was strengthened by a history of AP 
and especially RAP. However, some members of the working group felt that prior AP or 
RAP should be mandatory to make a diagnosis of Early CP. The likelihood that imaging 
features of mild pancreatic fibrosis represents Early CP is low in the absence of a history of 
AP. The relationship between the severity and timing of AP and the likelihood and timing of 
Early CP is unknown. The working group agrees that a careful history and documentation of 
risk factors such as a TIGAR-O list (9, 23, 77, 78), previous episodes of AP/RAP and their 
severity should be documented in all patients suspected to have CP.
Q8. Are genetic variants a required risk factor for Early Chronic Pancreatitis?
S8. Genetic variants are important risk factors for early chronic pancreatitis, but 
they are neither necessary nor sufficient to make a diagnosis.
(Quality assessment: moderate; Recommendation: strong; Agreement: strong).
Alpha Agreement: 0.85
Explanation: The discovery of high-risk, high penetrant and highly specific germ line 
mutations that can cause CP supports their use in the diagnosis of Early CP, especially as 
they are present before the onset of symptoms. The use and interpretation of a genetic test to 
evaluate a patient with possible Early CP is different in several ways than genetic testing in 
other settings. First, the testing is not done in asymptomatic patients to calculate life-long 
risk of developing a disease. Secondly, it can be used to determine which physiologic 
process is likely dysfunctional (e.g. duct secretion, trypsin regulation, unfolded protein 
response, oxidative stress). Third, evaluation of pathogenic modifier gene variants can be 
used to assess risk of more rapid progression to later stages of CP and complications (e.g. 
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CTRC linked to high risk with smoking (79), or CLDN2 linked to high risk of progression, 
especially with continued alcohol consumption (80–82)). Fourth, identification of 
pathogenic genetic variants in a symptomatic patient may identify the etiology of AP/RAP 
or pancreatitis-like symptoms and preclude the need for further workup. Finally, genetic 
testing is becoming important in identifying variants that predict response to specific genetic 
variants such as CFTR (83–86). Thus, in symptomatic patients genetic testing is not only 
valuable in determining the likelihood of Early CP, in contrast to other disorders, but it can 
also provide information on disease mechanisms and potential therapeutic targets.
Limitations in the availability and understanding of genetic data make obtaining a clear and 
accurate interpretation of individual genotypes challenging (87). Current genetic testing 
options contain a number of inherent challenges, including genotyping only a limited 
number of genes with small gene panels, incomplete coverage of key genes by focusing on a 
single nucleotide polymorphisms (SNPs), high homology between target genes, homologues 
and pseudogenes (88), and inability to detect many insertions, deletions, tandem repeats, 
copy number variants and fusion genes (89–92). In contrast, larger gene panels or exome/
genome sequencing provide more data but also identify greater numbers of variants of 
unknown significance and may miss correct sequencing of homologous or repeat regions.
The complexity of the CP syndrome is such that subsets of patients possess one or more 
highly pathogenic genetic variants associated with pancreatitis, while others have no 
identifiable genetic risk and yet develop End-stage CP. As with many disorders with a 
genetic component, physicians are faced with the burden of evaluating and managing genetic 
variants of unknown significance, and must recognize that there are likely many additional 
pathogenic variants yet to be discovered. Furthermore, genetic results cannot be interpreted 
outside of the clinical context, and the context of pancreatic diseases is complex. Genetic 
counseling is also important, both for the patient, and to help physicians who have a limited 
background in genetics or do not have the time to stay up to date with this dynamic field. 
However, the genetic counseling framework must be adapted for a complex disease when 
testing is used to evaluate the contribution of multiple modifiers that drive disease, rather 
than a Mendelian trait (93). Genetic testing can provide strong evidence of the etiology for 
RAP and Early CP, and help determine the mechanism of an evolving disease. Therefore, in 
the evaluation of Early CP, genetic testing for pancreatitis susceptibility genes and disease 
modifier genes in patients with RAP or evidence of Early-CP is clinically indicated when 
available (26, 78, 94), and should include both susceptibility genes and modifier genes with 
appropriate counseling.
Q9. Are environmental factors required risk factors for Early Chronic Pancreatitis?
S9. Environmental risk factors can provide important evidence in favor of early 
chronic pancreatitis, but they are neither necessary nor sufficient to make a 
diagnosis.
(Quality assessment: moderate; Recommendation: strong; Agreement: strong).
Alpha Agreement: 0.92
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Explanation: The presence of environmental factors in the right clinical setting highly 
supports the diagnosis of Early CP. The best studied environmental risk factors for chronic 
pancreatitis are heavy persistent alcohol use and cigarette smoking, and the effects are 
additive (95–98) (99). However, the majority of individuals with heavy or very heavy 
alcohol use do not develop chronic pancreatitis (100).
Both alcohol and smoking have direct effects on the pancreatic acinar and duct cells. 
Furthermore, during heavy use there are parenchymal changes in the pancreas that can be 
detected by image techniques such as endoscopic ultrasound (52, 54, 101, 102). In one study 
about 4% of healthy asymptomatic people without history and/or signs of pancreatic disease 
had at least three or more EUS abnormalities consistent with the diagnosis of CP (54). 
However, most of these changes stabilize or may resolve with cessation of the risk factor 
(103, 104). It is not known whether these features represent Early CP with resolution 
following elimination of the disease driver or whether they represents non-specific changes.
Persistent alcohol use and smoking are important but nonspecific risk factors for CP since 
some parenchymal changes can be seen that may not fulfill diagnostic criteria for CP using 
the Cambridge Scale. Use of predictive models that include genetic testing and history of AP 
or RAP may be helpful in classifying these patients in the future, but these clinical studies 
are lacking. The committee members and working group agree that during evaluation, a 
careful qualitative and quantitative history of alcohol and smoking use is required, and this 
information may increase the accuracy of a diagnosis of Early CP. The factors that define 
and drive the early fibro-inflammatory response require further study.
Q10. What is the differential diagnosis for Early Chronic Pancreatitis?
S10. The differential diagnosis for Early CP includes any other disorder with 
features that overlap the features of chronic pancreatitis as defined in the 
Mechanistic Definition of chronic pancreatitis.
(Quality assessment: moderate; Recommendation: strong; Agreement: strong).
Alpha Agreement: 0.83
Explanation: There are many disorders that result in changes in structure, function, 
clinical signs and symptoms and biomarkers that are similar to those that are thought to be 
present in Early CP. This overlap makes definitive diagnosis of Early CP difficult (4, 24, 25). 
The probability that early changes are due to Early CP is directly related to the likelihood of 
CP and inversely related to the likelihood of other disorders. The Mechanistic Definition 
defines the CP as a result of injury or stress (arising from the acinar cells or ducts) that 
generates a persistent inflammatory response (4, 24). This definition excludes autoimmune 
inflammation, inflammation and fibrosis arising from the islets related to long-standing 
diabetes mellitus, renal disease causing secondary effects on the pancreas, medications that 
alter the immune system (e.g. cyclosporine), age-related atrophy or fibrosis, IPMN, acinar 
cell cystadenoma, the desmoplastic response to pancreatic neoplasm, inflammation upstream 
of a duct obstructing mass, etc. Examples of the features that favor CP, or another diagnosis 
are nonspecific are listed in Table 2.
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In the future, clinical studies on patients evaluated for Early CP should also include the 
diagnostic tests and biomarkers that were used to address the differential diagnoses and 
clarify the true etiology of the underlying signs and symptoms. Such data will be useful for 
guiding future recommendations and guidelines.
Discussion:
The concept of Early-CP is well established, but there are no established definitions or 
diagnostic criteria. The goals in defining and developing specific criteria for Early CP are to 
facilitate the early and accurate diagnosis of the underlying disease so that effective, 
mechanism-based therapies can be developed, to minimize or reverse early disease features 
and to avoid late stage complications and poor outcomes (4, 25). A secondary effect is the 
avoidance of further unnecessary diagnostic testing, stopping inappropriate treatments and 
selecting better therapies. Early CP cannot be diagnosed by current imaging technologies 
alone and requires a new approach. In addition to imaging features the clinician must 
consider genetic and environmental risk factors, other biomarkers and functional tests, the 
clinical history and the clinical context. However, application of these concepts into practice 
is proving to be difficult. International consensus on the definition and criteria for 
diagnosing Early CP continues to be needed.
Central to the criteria for diagnosing any disorder is consideration of the risk: benefit ratio 
for doing the testing (e.g. EUS, ERCP) and implementing treatment (e.g. surgery, TPIAT) 
versus an alternative treatment or expectant observation until the disorder “declares itself”. If 
the outcome to be avoided is fibrosis, say in 10 years, and there is no specific therapy, then 
observation and symptomatic treatment may be indicated. If the outcome is severe pain and 
treatment delay results in continued suffering and high likelihood of developing an 
untreatable chronic pain syndrome, then early diagnosis and definitive treatments may be 
very beneficial (11, 105). The type of treatment planned for the current stage of the disease 
and severity of symptoms must also be evaluated. For example, the impact of treating a 
patient with Early CP with antioxidants (linked to a daily cost and inconvenience) is low, 
while the cost of treatment with surgery or TPIAT is high and the treatment is irreversible. 
Also, some treatments such as antioxidants appear to be more effective when started early 
(106). Other examples such as amlodipine (107) or camostat (108) may have positive effects 
but adequate studies are lacking and/or they may not be widely available. New clinical 
studies, utilizing new diagnostic approaches and designs are needed to provide evidence for 
future guidances.
The current report documents the level of agreement among international experts on various 
concepts related to Early CP. There was strong consensus on several statements including 
(Statement 2) the meaning of the word “Early”, (Statement 4) preserved pancreatic function 
and potentially reversible features, the importance of considering (Statement 8) genetic and 
(Statement 9) environmental etiologies and (Statement 10) on the differential diagnosis. 
Statements with moderate or low consensus included making a “definite” diagnosis of CP at 
earlier stages than currently available with the imaging criteria such as the Cambridge Score 
(Statements 1 & 6). Only moderate consensus was achieved with the definition of “chronic” 
in Early CP (Statement 3) and the interpretation and relative importance of imaging features 
Whitcomb et al. Page 17
Pancreatology. Author manuscript; available in PMC 2019 November 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(Statement 5). Furthermore, distinction between Early CP, probable CP, borderline CP and 
possible CP remains unclear, as does the implications of the use of these terms. However, 
Early CP could potentially be diagnosed, with a high degree of accuracy (i.e. not 100% 
denoting “definite”), using a combination of (a) identification of high risk factors for CP, (b) 
the absence of high risk factors for other disorders with features that overlap CP, (c) 
appropriate clinical context and (d) supportive biomarkers including imaging as proposed by 
the JPS. Depending on the purpose of the test (low or high risk intervention), the threshold 
for diagnosis could be set to maximize sensitivity and/or specificity. This requires 
prospective evaluation since at the present time our test panels lack the necessary accuracy 
for routine clinical practice.
Without a definition or diagnostic criteria for Early CP it has not bee possible to conduct 
high quality prospective studies. Several preliminary studies provide an estimate of the 
progression from Early CP to Established CP. In Japan, 113 patients with “Early CP” based 
on clinical factors and EUS and ERCP findings (based on the JPS 2010 Guidelines, Japanese 
Diagnostic Criteria 2009) (4) were recruited by 13 member institutes of the Japanese 
Research Committee of Intractable Pancreatic Diseases (RCIPD) by 31 December 2010 and 
followed up to 31 December 2012(T Shimosegawa, Report of the RCIPD, 2014). Five 
(9.6%) of these 52 patients progressed, 15 (28.8%) were unchanged and 32 (61.5%) 
improved. The diagnosis using the same guidelines two years later was “Definitive CP” in 2, 
“Probable CP” in 3 “Early Suspected CP” in 6 and ‘No symptoms” in 26 (109). Thus 
uncertainty as to any diagnosis of CP remained in over 50% of cases diagnosed with “Early 
CP” more than two years earlier. Partly based on these findings the JPS Guidelines altered 
the diagnostic criteria to include Clinical/Functional features as shown in Table 1 and Figure 
1 (24).
A 20-year study from Liverpool identified 40 (17%) of 807 patients with CP, with the 
findings of minimal change chronic pancreatitis (MCCP) or “Early CP” based on clinical 
factors and EUS findings. On follow-up only 12 (30%) went on to develop radiological 
and/or histological features of definite CP, with a median follow-up of 30 (IQR, 18.75–36.5) 
months. Five (12.5%) had complete regression of MCCP changes and the remaining 23 
(57.5%) demonstrated no progression of radiological features to support a diagnosis of CP 
(110). These studies emphasize the need for better initial diagnostic criteria and prospective 
tracking of patient trajectory in larger cohorts.
In contrast to patients presenting with EUS findings as the initial sign of CP, Skinazi et. al. 
(111) followed 114 alcoholic patients without CP who presented with an initial attack of 
acute alcoholic pancreatitis and were followed prospectively for a minimum of two years. 
Definite CP was identifying in 101 patients (88.6%) by a combination of pancreatic 
calcifications (n = 71), mild to severe imaging abnormalities (n = 19), histological 
examination (n = 8), and perioperative data (n = 3). Four additional patients (3.5%) 
developed DM as the primary clinical feature along with sufficient clinical and imaging 
evidence to classify them using traditional criteria as Probable CP. This prospective study 
confirms the link between AP and CP, and documents the high risk of progression from AP 
to CP in patients with alcoholism.
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One of the major challenges for clinicians is to make a diagnosis in patients with or without 
a history of AP who have persistent exocrine pancreatic insufficiency, pancreatic atrophy, 
post AP diabetes mellitus, or recurrent-persistent abdominal pain following AP without 
morphologic changes of advanced CP. In some cases clinicians have diagnosed these 
patients as “minimal change CP” or “atypical CP” (112, 113). The opportunity to conduct 
future studies that utilize risk profiles, biomarkers of pancreatic injury or stress, tissue 
analysis when available, responses to targeted treatment and outcomes may resolve these 
questions. Better definitions of Early CP, facilitated by the mechanistic definition that helps 
identify the underlying disease drivers and potential therapeutic targets is an excellent 
example of precision medicine. This more holistic and individualized approach should lead 
to a more accurate diagnosis of patients with Early CP, and facilitate prospective studies that 
better define the natural history, rates of progression and more homogenous cohorts for 
intervention studies. It is clear that the approach to the definition and diagnosis of Early CP 
cannot be dependent on morphological changes.
Conclusions.
New approaches to the definition and diagnosis of Early CP should use risk factor analysis, 
biomarkers, clinical context and new models of disease with assessment of overall sensitivity 
and specificity integrated with risk: benefit analysis of treatment. Because these concepts are 
new, well-designed prospective clinical studies with long-term follow-up need to be 
conducted.
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Figure 1. 
Method of diagnosis Definite CP, Probable CP and Early CP using the Japanese Pancreas 
Society Clinical Guidelines, 2015. Clinical and imagine features of early CP are in Table 1. 
Modified from Japanese clinical guidelines 2015, Ito, et al (24).
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Table 1.
Early CP diagnosis from the Japanese clinical guidelines 2015.
A. Clinical/Functional Features.
1 recurrent upper abdominal pain (two or more attacks)
2 abnormal serum/urine enzyme levels,
3 abnormal exocrine function, with an additional criteria for Early CP of
4 continuous heavy drinking (> 80g/d).
B. Imaging findings of early chronic pancreatitis (either a or b)
a. More than two among the following seven features of EUS findings including at least one of (1–4)
1. Lobularity with honeycombing
2. Lobularity without honeycombing
3. Hyperechoic foci without shadowing
4. Stranding
5. Cysts
6. Dilated side branches
7. Hyperechoic MPD margin
b. Irregular dilatation of more than three duct branches on ERCP
EUS endoscopic ultrasonography, MPD main pancreatic duct, ERCP, endoscopic retrograde cholangiopancreatography
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Table 2.
Factors affecting the likelihood of CP. AP, acute pancreatitis; CP, chronic pancreatitis; DM, diabetes mellitus; 
EPI, exocrine pancreatic insufficiency; IPMN, intrapancreatic mucinous neoplasm; PDAC, pancreatic ductal 
adenocarcinoma; RAP, recurrent acute pancreatitis; SDS, Shwachman-Diamond Syndrome.
Pancreatology
Favors CP
 CP Genetic Risk Factors
 CP Genetic Modifiers
 Acute Pancreatitis
 RAP
 Characteristic Pain
 Chronic alcohol abuse and/or smoking (with AP)
Favors other Dx:
 Longstanding DM (e.g. >5 years before first AP)
 Older age
 Renal disease (advanced)
 Drugs (e.g. cyclosporine)
 Elevated IgG4
 High risk of PDAC
 IPMN
 EPI disorders (e.g. SDS)
Nonspecific
 Alcohol Use (without AP)
 Tobacco Smoking (without 
AP)
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